| Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? |
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern. |
zacks.com |
2025-05-16 12:51:06 |
Czytaj oryginał (ang.) |
| 3 Unconventional Cannabis Stocks to Watch in 2025 |
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025. |
zacks.com |
2025-04-29 13:15:40 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-18 14:56:03 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity |
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND. |
globenewswire.com |
2025-03-28 10:00:00 |
Czytaj oryginał (ang.) |
| After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) |
Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-03-20 12:35:23 |
Czytaj oryginał (ang.) |
| After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP) |
Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-03-19 12:35:19 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know |
Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-03-13 15:14:41 |
Czytaj oryginał (ang.) |
| CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 |
NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) (“Corbus” or the “Company”), announced that data from its US and UK conducted first-in-human dose escalation clinical study (“Western study”) of CRB-701 (SYS6002) is being presented today at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). |
globenewswire.com |
2025-02-14 09:30:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU |
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe (“Western study”) of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. ASCO GU will be held in San Francisco, CA February 13-15, 2025. |
globenewswire.com |
2025-02-11 09:30:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference |
NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings. |
globenewswire.com |
2025-01-28 10:00:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings. |
globenewswire.com |
2025-01-06 10:00:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors |
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment |
globenewswire.com |
2024-12-09 09:00:00 |
Czytaj oryginał (ang.) |
| FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer |
NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload. |
globenewswire.com |
2024-12-03 09:00:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies |
Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. |
seekingalpha.com |
2024-11-11 06:12:49 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference |
NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA. |
globenewswire.com |
2024-10-29 10:00:00 |
Czytaj oryginał (ang.) |
| Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) |
NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined doses (1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg and 4.5 mg/kg) and will be followed by Part B (dose optimization) and Part C (dose expansion) that will determine recommended/optimized doses and seek preliminary efficacy signals. |
globenewswire.com |
2024-10-16 12:00:00 |
Czytaj oryginał (ang.) |
| Check Out Last Week's Big Insider Buying: Biotechs, Energy, and More |
24/7 Wall St. Insights Summer gave way to autumn this past week, and notable insider buying continued. |
247wallst.com |
2024-09-29 13:15:16 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit |
NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital Markets' Oncology Summit, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled Capitalizing on Validated Mechanism in Oncology. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings. |
globenewswire.com |
2024-09-26 12:00:00 |
Czytaj oryginał (ang.) |
| Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now |
Corbus Pharmaceuticals Holdings, Inc. CRBP received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s NVO mid-stage data on its obesity drug. |
benzinga.com |
2024-09-23 18:01:37 |
Czytaj oryginał (ang.) |
| 3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024 |
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. |
247wallst.com |
2024-09-08 11:43:58 |
Czytaj oryginał (ang.) |
| Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say |
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday. |
marketwatch.com |
2024-08-26 16:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-08-26 14:55:26 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung |
NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. |
globenewswire.com |
2024-08-20 12:00:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why |
Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-08-09 17:01:25 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade |
The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-08-09 14:55:37 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update |
NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024. |
globenewswire.com |
2024-08-06 12:00:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August |
NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events. |
globenewswire.com |
2024-07-30 12:50:00 |
Czytaj oryginał (ang.) |
| Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet |
Prospects for interest rate cuts are fueling speculations about which small-cap stocks will be winners when they hit. Because smaller companies don't have the same financial access as larger stocks, they are forced to borrow money at higher cost, which impacts their ability to grow. |
investorplace.com |
2024-06-30 14:13:35 |
Czytaj oryginał (ang.) |
| Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025 |
Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively. The global urothelial carcinoma market is expected to reach $6.82 billion in 2032. It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030. |
seekingalpha.com |
2024-06-03 17:03:00 |
Czytaj oryginał (ang.) |
| SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 |
NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate , has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center. |
globenewswire.com |
2024-06-01 14:00:00 |
Czytaj oryginał (ang.) |
| Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference |
NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL. |
globenewswire.com |
2024-05-30 12:00:00 |
Czytaj oryginał (ang.) |